Our Mission is to develop the broadest range of clinical therapies with our breakthrough technology to benefit as many patients as possible suffering from metastatic bone cancer.

“Research never ceases at Zetagen because cancer never rests…”

We are appreciative to have the financial support of our investors and the National Institute of Health (NIH) through their variety of Small Business Innovation Research (SIBR) programs to support our research. Zetagen’s preclinical research is funded through a series of phase I and II grants from the National Cancer Institute (NCI) and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the NIH.

ZetaMet™ was recently awarded a Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the treatment of metastatic bone cancer. Currently, ZetaMet™ is being reviewed by the FDA and Health Canada for a human clinical study for patients living with metastatic breast cancer. Enrollment for this study is scheduled for Q2-2022. Zetagen has several therapies in various stages of development.

ZetaDent -Osteo-Inductive Biologic System